Since the beginning of clinical activity in 2011, approximately 600 patients has been treated with hadrons in CNAO (National Center for Oncological Hadrontherapy), among which 42 were sacral chordoma undergoing carbon ion radiotherapy (CIRT) with a radical intent. The aim of the current study is to analyze the feasibility of the insertion of a newly customized spacer prior CIRT in sacral chordoma patients, in terms of procedure validation and patient tolerance, in selected cases where the sacral chordoma is contiguous to the rectum or the bowel loops in order to safely escalate the dose to the tumor target.
Material and Methods:
Since 2014 , 6 consecutive sacral chordoma patients (3 males and 3 females) eligible for active scanning beam delivery CIRT at CNAO (prescribed dose 70.4 GyE in 16 fractions), were enrolled for spacer placement at IRCCS Policlinico San Matteo -Dept. of General Surgery. For each patient silicone spacer was shaped according to intraoperative findings from a 10x10 cm silicone sheet with a width of 1 mm (Distrex, Padua, Italy) . Prior to the surgery and clinical use, a variety of measurements was performed to evaluate the physical stability of the spacer during and after irradiation, as well as its main properties when exposed to carbon ion beams. During CIRT, at the end and each 3 months afterwards, patients were followed up for acute and late CIRT toxicity with clinical visit and high field magnetic resonance (MRI).
Results: Three patients underwent laparotomic and 3laparoscopic spacer placement. A representative CIRT plan recalculation performed on one of the enrolled patient CT performed before spacer insertion showed that during CIRT the presence of the spacer keeps digestive tract far away from the irradiated area, thus the radiation field is unaffected by rectum filling or intestine movement. Patient enrolled in the study did not show any gastrointestinal toxicity during CIRT or at follow up. Patient imaging during follow up did not show anatomic variations.
Conclusion:
Silicone spacer placement is a valuable tool for safe dose escalation in sacral chordoma patients undergoing CIRT.
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Adjuvant concurrent chemoradiotherapy in soft tissue sarcomas of the limbs: an effective strategy. Material and Methods: From 1991 to 2012, 68 patients with primary high grade STS of the limb were treated in our institution with an adjuvant concurrent chemoradiotherapy, following limb sparing surgery The median age was 47.5 years (range, 19 to 74). The most common location was the thigh (56%). The resection was complete (R0) and marginal (R1) in 46 (68%), and 22 (32%), respectively. The median tumor size was 6 cm (range, 8 to 20cm), deep in 83% of cases, and grade was 2 (FNCLCC) in 28 patients (42%) and 3 in 38 (58%), 2 missing. Adjuvant radiotherapy was delivered by brachytherapy (BRT) plus external radiotherapy (EBRT) in 26 patients (38%) and by EBRT alone in 42 (62%). The median dose of BRT and EBRT were respectively 20Gy (range 12 to 30Gy) and 60Gy (range, 45 to 70). The median time between surgery and EBRT was 48 days (range, 20 to 140). Concurrent chemotherapy (CT) was a combination of doxorubicin (60 mg/m2 total dose (TD) and ifosfamide (7,5 g/m2 TD), with a median number of 4 cycles (range, 1-4).
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Results:
With a median follow-up of 105 months (CI95% 89-125), the 5-year disease-free survival and overall survival rates were 67%(CI95 53.9-77) and 81%(CI95 68-89); 25 relapses were observed (6 local, 18 distant, and 1 local and distant). A severe (grade 3-4) hematologic toxicity was observed in 32% of cases, mainly leucopenia; 13 patients (20%) experienced a dose reduction of CT. Severe non hematologic complications occurred in 15 patients (22%), mainly acute cutaneous toxicity (14 patients, 21%). Six patients (10%) experienced an EBRT interruption. Severe wound complications were very rare (2 absesses), without secondary operation for wound care. In univariate analysis, median EBRT dose was a prognostic factor for hematologic severe complications, the median dose being 64Gy in patients with grade 3-4 toxicities vs 56Gy in patients with grade 1-2 toxicities;p=0.01. Tumor location was a prognostic factor for grade 3-4 wound complications and acute dermatitis. Indeed, 50% of complications were grade 3-4 (5/10) when tumor was located in upper limb, vs 17% in inferior limb (10/58); (p=0.035). No correlation between age, sexe, tumor size, and toxicity was found.
Conclusion:
Adjuvant concurrent chemoradiotherapy is efficient, feasible and well-tolerated in soft tissue sarcomas of the limbs. Purpose or Objective: Kaposi sarcoma (KS) is a vascular tumor that can affect the skin and the mucosa of the digestive, respiratory and urinary tracts, as well as the lynphatic system. It is associated to human herpes virus 8 (HHV-8). There are three principal variants: Classic KS which affects older people (mediterranean and jewish askenazi); Endemic KS which mainly affectss african children, is a fulminant lymphadenopathic desease, and HIV-associated KS which affects homosexual men. Patients with Classic KS have skin macules on the legs that enlarge and coalesce into plaques and nodules. Radiotherapy is an effective treatment for localized lesions.
EP-1409 Neuropathic pain a secondary-effect in Classic Kaposi
Material and Methods:
We retrospectively analized patients with classic KS treated in our department between 2004 and 2014. Until 2012, all our patients were treated with a 3 Gy per fraction, 30 Gy total dose treatment schedule. After this date most of our patientes were treated with a 2 Gy per fraction, 40 Gy total dose treatment schedule. All patients were treated with the same technique: two paralel-opposed 6 Mv photom fields on both legs submerged into water, in order to homogenize the dose on the entire surface, and as a bolus effect. We observed that some patients treated with 3 Gy per fraction schedule, had neuropathic pain in both legs, ________________________________________________________________________________ after the end of the radiation treatment, which required the use of high dose-opioid and gabaergic pain relievers, chronically. In fact, this was the main factor to consider in our study. Local control was analized too.
Results:
Eight patients were treated with 3 Gy /fraction, four of them suffered neuropathic pain in radiation field that required chronic drug treatment. (RR 50%). None of the five patients treated with the 2 Gy per fraction technique had neuropathic pain in legs.
Conclusion:
Our preliminary results indicate that the 2 Gy per fraction treatment avoids the onset of neuropathic pain after the radiation treatment. Althoug the patient recruitment was low, we can afirm that both radiation techniques were very useful in the classic KS local control. The 2 Gy per fraction treatment was not associated to neuropathic pain, compared with the hypofractioned radiation treatment. 
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